Diabetic Medicine (DIABETIC MED)

Publisher: British Diabetic Association, Wiley

Journal description

Diabetic Medicine is an information exchange on all aspects of diabetes mellitus and aims to publish reviews and original articles in the fields of diabetes research and practice. It particularly focusses on basic and applied research of direct relevance to clinical diabetes and its scope ranges from fundamental research to delivery of better health care. The journal provides a multidisciplinary forum combining original articles; comprehensive reviews of research and clinical issues; comment, news and corespondence.

Current impact factor: 3.06

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 3.064
2012 Impact Factor 3.241
2011 Impact Factor 2.902
2010 Impact Factor 3.036
2009 Impact Factor 2.871
2008 Impact Factor 3.172
2007 Impact Factor 2.97
2006 Impact Factor 2.484
2005 Impact Factor 2.725
2004 Impact Factor 2.621
2003 Impact Factor 2.235
2002 Impact Factor 2.172
2001 Impact Factor 2.678
2000 Impact Factor 2.732
1999 Impact Factor 2.17
1998 Impact Factor 1.63
1997 Impact Factor 1.601
1996 Impact Factor 1.904
1995 Impact Factor 1.353
1994 Impact Factor 1.277
1993 Impact Factor 1.353
1992 Impact Factor 1.306

Impact factor over time

Impact factor

Additional details

5-year impact 3.30
Cited half-life 7.10
Immediacy index 0.64
Eigenfactor 0.02
Article influence 1.09
Website Diabetic Medicine website
Other titles Diabetic medicine (Online), Diabetic medicine
ISSN 0742-3071
OCLC 37978649
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • Some journals have separate policies, please check with each journal directly
    • On author's personal website, institutional repositories, arXiv, AgEcon, PhilPapers, PubMed Central, RePEc or Social Science Research Network
    • Author's pre-print may not be updated with Publisher's Version/PDF
    • Author's pre-print must acknowledge acceptance for publication
    • On a non-profit server
    • Publisher's version/PDF cannot be used
    • Publisher source must be acknowledged with citation
    • Must link to publisher version with set statement (see policy)
    • If OnlineOpen is available, BBSRC, EPSRC, MRC, NERC and STFC authors, may self-archive after 12 months
    • If OnlineOpen is available, AHRC and ESRC authors, may self-archive after 24 months
    • Publisher last contacted on 07/08/2014
    • This policy is an exception to the default policies of 'Wiley'
  • Classification
    ​ yellow

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the glomerular haemodynamic profile of patients with Type 1 diabetes with either renal hyperfiltration (GFR≥135 ml/min/1.73m(2) ) or renal normofiltration (GFR 90-134 ml/min/1.73m(2) ) during euglycaemic and hyperglycaemic conditions, and to compare this profile with that of a similar group of healthy control subjects. Gomez's equations were used to derive afferent and efferent arteriolar resistances, glomerular hydrostatic pressure and filtration pressure. At baseline, during clamped euglycaemia, patients with Type 1 diabetes and hyperfiltration had lower mean ± sd afferent arteriolar resistance than both those with Type 1 diabetes and normofiltration (914 ± 494 vs. 2065 ± 597 dyne/s/cm(5) ; P<0.001) and healthy control subjects (1676 ± 707 dyne/s/cm(5) ; p<0.001). By contrast, efferent arteriolar resistance was similar in the three groups. Patients with Type 1 diabetes and hyperfiltration also had higher mean ± sd glomerular hydrostatic pressure than both healthy control subjects and patients with Type 1 diabetes and normofiltration (66 ± 6 vs. 60 ± 3 vs. 55 ± 3 mmHg; P<0.05). Similar findings for afferent arteriolar resistance, efferent arteriolar resistance, glomerular hydrostatic pressure and filtration pressure were observed during clamped hyperglycaemia. Hyperfiltration in Type 1 diabetes is primarily driven by alterations in afferent arteriolar resistance rather than efferent arteriolar resistance. Renal protective therapies should focus on afferent renal arteriolar mechanisms through the use of pharmacological agents that target tubuloglomerular feedback, including sodium-glucose cotransporter 2 inhibitors and incretins. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetic Medicine 02/2015; DOI:10.1111/dme.12717
  • [Show abstract] [Hide abstract]
    ABSTRACT: We would like to thank van der Donk and Pouwer for taking the time to reflect critically on the abridged version of our Cochrane systematic review on psychological and pharmacological interventions for depression in patients with diabetes mellitus [1]. They raise some important methodological concerns on the conducting and reporting of our review which, if correct, could have biased the interpretation of our findings. As Cochrane authors, we adhere to the Cochrane Collaboration's core aim of trusted evidence, which requires investigators to aim for the highest methodological standards in conducting their reviews. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetic Medicine 02/2015; DOI:10.1111/dme.12715
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the relationship between plasma betatrophin concentrations and insulin secretion capacity in people with Type 2 diabetes. Glucagon stimulation tests (1 mg) were performed in 70 people with Type 2 diabetes after an overnight fast. Plasma betatrophin concentrations were measured using an enzyme-linked immunosorbent assay. Insulin secretion capacity was evaluated by measuring increments of C-peptide concentration in response to glucagon stimulation, and creatinine clearance was determined by comparing creatinine concentrations in serum and 24-h urine samples. Plasma betatrophin concentrations were positively correlated with duration of Type 2 diabetes (r = 0.34, P = 0.003), and negatively correlated with increments of C-peptide concentration (r = 0.37, P = 0.001) and creatinine clearance (r = 0.37, P = 0.001). The correlation with increments of C-peptide concentration remained significant after adjustment for age and duration of Type 2 diabetes (r = 0.25, P = 0.037). Multivariate analysis identified age and increments of C-peptide concentration as independent factors associated with plasma betatrophin levels. Plasma betatrophin levels inversely correlate with insulin secretion capacity, suggesting that betatrophin levels are regulated by insulin secretion capacity in humans. © 2015 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
    Diabetic Medicine 01/2015; DOI:10.1111/dme.12696
  • [Show abstract] [Hide abstract]
    ABSTRACT: To develop and validate the Diabetes Family Impact Scale, a scale to measure the impact of diabetes on families. The Diabetes Family Impact Scale was developed by an iterative process, with input from multidisciplinary diabetes providers and parents of children with Type 1 diabetes. The psychometric properties of the Diabetes Family Impact Scale were assessed in parents of children with Type 1 diabetes. This assessment included internal consistency, convergent validity and exploratory factor analysis. Parents (n = 148) of children (mean ± sd age 12.9 ± 3.3 years) with Type 1 diabetes (mean ± sd duration 6.2 ± 3.6 years) completed the 15-item Diabetes Family Impact Scale. After eliminating one item, the 14-item measure demonstrated good internal consistency (Cronbach's α = 0.84). Correlations between the Diabetes Family Impact Scale and measures of parent diabetes burden (r = 0.48, P < 0.0001), stressful life events (r = 0.28, P = 0.0007), and child's quality of life (r = -0.52 and -0.54, P < 0.0001 for generic and diabetes-specific quality of life, respectively) supported the convergent validity of the instrument. Factor analysis identified four factors corresponding to the four survey domains (school, work, finances and family well-being). The Diabetes Family Impact Scale measures diabetes-specific family impacts with good internal consistency and convergent validity and may be a useful tool in clinical and research settings. © 2015 The Authors. Diabetic Medicine © 2015 Diabetes UK.
    Diabetic Medicine 01/2015; DOI:10.1111/dme.12689
  • [Show abstract] [Hide abstract]
    ABSTRACT: To explore the difficulties parents encounter in trying to achieve clinically recommended blood glucose levels and how they could be better supported to optimize their child's glycaemic control. In-depth interviews were conducted with 54 parents of children with Type 1 diabetes (≤12 years). Data were analysed thematically. Parents described being reluctant and finding it difficult to keep their child's blood glucose levels consistently within clinically recommended ranges. As well as worrying about their child's ability to detect/report hypoglycaemia, parents highlighted a multitude of factors that had an impact on their child's blood glucose levels and over which they could exercise little control. These included: leaving their child with other caregivers who could not be trusted to detect hypoglycaemia; difficulties remotely monitoring and regulating their child's food consumption and activity; and physical and social changes accompanying childhood development. Most parents used two sets of blood glucose targets, with clinically recommended targets employed when their child was in their immediate care and higher targets when in the care of others. Parents described health professionals as lacking in understanding of the difficulties of keeping blood glucose within target ranges and needing more empathetic, tailored and realistic advice. It is not parents' fear of hypoglycaemia in isolation that leads to decisions to raise their child's blood glucose but, rather, parental fear in conjunction with other factors and considerations. Hence, to improve diabetes management in children, these factors may need to be addressed; for instance, by training others in diabetes management and using new technologies. Changes to consultations are also recommended. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Diabetic Medicine 12/2014; DOI:10.1111/dme.12660
  • Diabetic Medicine 11/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Living with Type 1 diabetes is not easy given the relentless demands of self-management tasks and continual fear of low glucose levels [1]. This fear is understandable, with the Diabetes Control and Complications Trial reporting intensive insulin therapy being associated with an increased risk of severe hypoglycaemia and 43% of episodes of events occurring during sleep [2]. Unsurprisingly, therefore, fear of low glucose levels during the night represents a major concern for people living with diabetes and their families and can be a potential barrier to achieving optimal glycaemic control [3].This article is protected by copyright. All rights reserved.
    Diabetic Medicine 11/2014; DOI:10.1111/dme.12699
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimInsulin therapies with prandial injections offer the possibility to skip snacks or omit meals. It is unclear how many people with insulin-treated diabetes mellitus eat snacks and whether they snack for their own comfort or only on the recommendation of healthcare professionals.Methods In 2004, 163 consecutive people with insulin-treated diabetes seen in a university outpatient department were interviewed regarding their diet and degree of satisfaction with their meals. Fifty-five had Type 1 diabetes [age 47 years; diabetes duration 18 years; BMI 27 kg/m2; HbA1c 62 mmol/mol (7.8%)], 53 had Type 2 diabetes with biphasic insulin therapy [age 68 years; diabetes duration 17 years; BMI 31 kg/m2; HbA1c 60 mmol/mol (7.6%)] and 55 had Type 2 diabetes with prandial insulin therapy [age 60 years; diabetes duration 16 years; BMI 33 kg/m2; HbA1c 59 mmol/mol (7.6%)].ResultsEighty per cent of those with Type 1 diabetes ate snacks, together with 77% of the Type 2 diabetes/biphasic group and 62% of the Type 2 diabetes/prandial group. Most participants (91% Type 1 diabetes, 88% Type 2 diabetes/biphasic group, 82% Type 2 diabetes/prandial group) liked to have snacks. The time at which they ate snacks was the same for both diabetes types. There were no differences between participants with Type 1 diabetes who snacked and those who did not in terms of age (P = 0.350), BMI (P = 0.368), HbA1c (P = 0.257) and time since diagnosis (P = 0.846). Participants with Type 2 diabetes who ate snacks were older than those who did not (biphasic: P = 0.006; prandial: P = 0.008). There were no differences in terms of BMI (biphasic: P = 0.731; prandial: P = 0.393), HbA1c (biphasic: P = 0.747; prandial: P = 0.616) and time since diagnosis (biphasic: P = 0.06; prandial: P = 0.620).Conclusions Most people with insulin-treated diabetes eat snacks voluntarily and not because of physicians' instructions. There were no correlations between the use of snacks and HbA1c, BMI and time since diagnosis, except that the participants with Type 2 diabetes who ate snacks were older.
    Diabetic Medicine 10/2014; 32(3). DOI:10.1111/dme.12616
  • Diabetic Medicine 06/2014; 31(6):637-8. DOI:10.1111/dme.12454
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimTo compare the prevalence and clinical features of HNF1-related MODY and HNF1-related MODY in Japanese. Methods We enrolled 230 Japanese patients with suspected MODY and examined them for HNF1 and HNF1 mutations. We characterized the clinical features of HNF1-related MODY (HNF1-MODY) and HNF1-related MODY (HNF1-MODY). ResultsSix patients had HNF1 mutations, four of which were large gene deletions and 24 patients had HNF1 mutations, which included one gene deletion. The mean fasting plasma glucose level at onset of HNF1-MODY was considerably higher and the age of onset of HNF1-MODY was considerably older than they were for HNF1-MODY, while the mean BMI and C-peptide index at onset were similar. Three patients with HNF1-MODY were found to have dorsal pancreatic agenesis and four of them had whole-gene deletion. Five of the patients with HNF1-MODY had insulin secretion defects and were treated with insulin, and four of these did not have a parent with overt diabetes. ConclusionHNF1-MODY may present as -cell dysfunction in Japanese rather than as hyperinsulinaemia, which it does among European/American. This dysfunction might result from an intrinsically lower capacity for insulin secretion in Japanese. HNF1-MODY has an older age of onset than HNF1-MODY, which may suggest lower penetrance of the disease. In addition, HNF1-MODY has a broad spectrum of clinical manifestations, some of which are detectable by imaging. This may be helpful in some cases for selecting HNF1-MODY candidates for genetic testing. What's new? The Japanese patients with hepatocyte nuclear factor 1 (HNF1)-related maturity-onset diabetes of the young (HNF1-MODY) in the present study all had a diabetes onset age of < 25years, whereas the onset age of HNF1-MODY is > 25years in 40% of European/American patients. Fasting plasma glucose levels at onset and the age of onset of HNF1-related maturity-onset diabetes of the young (HNF1-MODY) were considerably higher and older, respectively, than those of HNF1-MODY in our Japanese study population. HNF1-MODY generally presents as -cell dysfunction in Japanese, unlike in European/American in whom it presents as hyperinsulinaemia, partly because of the intrinsically lower capacity for insulin secretion in Japanese.
    Diabetic Medicine 06/2014; 31(6). DOI:10.1111/dme.12416
  • Diabetic Medicine 06/2014; 31(6). DOI:10.1111/dme.12463
  • Diabetic Medicine 03/2014; 31(Suppl 1):22.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Aims/hypothesis: To determine the stability of type 2 diabetes patients’ beliefs about their diabetes over three years, following diagnosis. Methods: Data were collected as part of a multicentre cluster randomised controlled trial of a 6 hour self-management program, across 207 general practices in the UK. Participants in the original trial were eligible for follow-up with biomedical data (glycated haemoglobin (HbA1c) levels, blood pressure, weight, blood lipid levels ) collected at the practice and questionnaire data collected by postal distribution and return. Psychological outcome measures were depression (HADS) and diabetes distress (PAID). Illness beliefs were assess by scales from the Illness Perceptions Questionnaire- Revised and the Diabetes Illness Representations Questionnaire. Results: At 3 year follow-up, all post intervention difference in illness beliefs between intervention and control group remained significant, with perceptions of the duration of diabetes, seriousness of diabetes and perceived impact of diabetes unchanged over the course of the 3 years follow-up. The control group reported greater understanding of diabetes over follow-up, and the intervention group reported decreased responsibility for diabetes outcomes over follow-up. After controlling for 4 month levels of distress and depression, perceived impact of diabetes at 4 months remained a significant predictor of distress and depression at 3 years follow-up. Conclusions/interpretation: Peoples’ beliefs about diabetes are formed quickly after diagnosis, and thereafter seem to be relatively stable over extended follow-up. These early illness beliefs are predictive of later psychological distress, and emphasize the importance of initial context and provision of diabetes care in shaping participants’ future well-being
    Diabetic Medicine 03/2014; Accepted - In Press.
  • Diabetic Medicine 03/2014;
  • Diabetic Medicine 03/2014; 31(1):48-49.
  • Diabetic Medicine 02/2014; 31(2). DOI:10.1111/dme.12321
  • Diabetic Medicine; 01/2014
  • Diabetic Medicine 01/2014; 31:27.
  • Diabetic Medicine 12/2013; 30(12). DOI:10.1111/dme.12304